Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND Multiple myeloma remains incurable, and heavily pretreated patients with relapsed or refractory disease have few good treatment options. Belantamab mafodotin showed promising results in a phase 2 study of patients with relapsed or refractory multiple myeloma at second or later relapse and a manageable adverse event profile. We aimed to assess the safety and efficacy of belantamab mafodotin in a phase 3 setting. METHODS In the DREAMM-3 open-label phase 3 study, conducted at 108 sites across 18 countries, adult patients were enrolled who had confirmed multiple myeloma (International Myeloma Working Group criteria), ECOG performance status of 0-2, had received two or more previous lines of therapy, including two or more consecutive cycles of both lenalidomide and a proteasome inhibitor, and progressed on, or within, 60 days of completion of the previous treatment. Participants were randomly allocated using a central interactive response technology system (2:1) to receive belantamab mafodotin 2·5 mg/kg intravenously every 21 days, or oral pomalidomide 4·0 mg daily (days 1-21) and dexamethasone 40·0 mg (20·0 mg if >75 years) weekly in a 28-day cycle. Randomisation was stratified by previous anti-CD38 therapy, International Staging System stage, and number of previous therapies. The primary endpoint was progression-free survival in all patients who were randomly allocated. The safety population included all randomly allocated patients who received one or more doses of study treatment. This trial is registered with ClinicalTrials.gov, NCT04162210, and is ongoing. Data cutoff for this analysis was Sept 12, 2022. FINDINGS Patients were recruited between April 2, 2020, and April 18, 2022. As of September, 2022, 325 patients were randomly allocated (218 to the belantamab mafodotin group and 107 to the pomalidomide-dexamethasone group); 184 (57%) of 325 were male and 141 (43%) of 325 were female, 246 (78%) of 316 were White. Median age was 68 years (IQR 60-74). Median follow-up was 11·5 months (5·5-17·6) for belantamab mafodotin and 10·8 months (5·6-17·1) for pomalidomide-dexamethasone. Median progression-free survival was 11·2 months (95% CI 6·4-14·5) for belantamab mafodotin and 7·0 months (4·6-10·6) for pomalidomide-dexamethasone (hazard ratio 1·03 [0·72-1·47]; p=0·56). Most common grade 3-4 adverse events were thrombocytopenia (49 [23%] of 217) and anaemia (35 [16%]) for belantamab mafodotin, and neutropenia (34 [33%] of 102) and anaemia (18[18%]) for pomalidomide-dexamethasone. Serious adverse events occurred in 94 (43%) of 217 and 40 (39%) of 102 patients, respectively. There were no treatment-related deaths in the belantamab mafodotin group and one (1%) in the pomalidomide-dexamethasone group due to sepsis. INTERPRETATION Belantamab mafodotin was not associated with statistically improved progression-free survival compared with standard-of-care, but there were no new safety signals associated with its use. Belantamab mafodotin is being tested in combination regimens for relapsed or refractory multiple myeloma. FUNDING GSK (study number 207495).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationUpdated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159009 · Cited by 350
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer · doi:10.1002/cncr.33809 · Cited by 144
Self-citation
Research works printed but not linked: 15
- Gandhi, 2019, Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, Leukemia, 33, 2266, 10.1038/s41375-019-0435-7 · DOI · Paper page
- Lee, 2016, Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma, Br J Haematol, 174, 911, 10.1111/bjh.14145 · DOI · Paper page
- O'Connor, 2004, BCMA is essential for the survival of long-lived bone marrow plasma cells, J Exp Med, 199, 91, 10.1084/jem.20031330 · DOI · Paper page
- Montes de Oca, 2021, Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo, Mol Cancer Ther, 20, 1941, 10.1158/1535-7163.MCT-21-0035 · DOI
- Tai, 2015, Targeting B-cell maturation antigen in multiple myeloma, Immunotherapy, 7, 1187, 10.2217/imt.15.77 · DOI · Paper page
- Tai, 2014, Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma, Blood, 123, 3128, 10.1182/blood-2013-10-535088 · DOI · Paper page
- Lonial, 2021, Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM), Blood Cancer J, 11, 103, 10.1038/s41408-021-00494-4 · DOI · Paper page
- Huang, 2022, Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments, Pharm Stat, 21, 865, 10.1002/pst.2198 · DOI
- Cocks, 2012, Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, Eur J Cancer, 48, 1713, 10.1016/j.ejca.2012.02.059 · DOI · Paper page
- Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139 · DOI · Paper page
- Alegre, 2023, Real-world outcomes of belantamab mafodotin for relapsed/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP), Oncol Ther, 11, 83, 10.1007/s40487-022-00212-5 · DOI
- Hultcrantz, 2021, Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience, Blood, 138
- Eaton, 2015, Ocular adverse events associated with antibody-drug conjugates in human clinical trials, J Ocul Pharmacol Ther, 31, 589, 10.1089/jop.2015.0064 · DOI · Paper page
- Trudel, 2022, Belantamab mafodotin in combination with pomalidomide and dexamethasone demonstrates durable responses in triple class exposed/refractory multiple myeloma, Blood, 140, 7306, 10.1182/blood-2022-160445 · DOI
- Trudel, 2021, Part 1 Results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM), Blood, 138
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405090 · Cited by 199
Self-citationHungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00330-4 · Cited by 35
Self-citation
Metadata
- Authors
- Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J., & Weisel, K.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 10
- Issue
- 10
- Pages
- e801-e812
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W4387246764
- Cited by
- 138
- References
- 4
- FWCI
- 24.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Seagen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. https://app.cochat.ai/papers/10.1016/s2352-3026(23)00243-0
- The paper
- Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., . . . Weisel, K. (2023). Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(23)00243-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.